<DOC>
	<DOCNO>NCT00785915</DOCNO>
	<brief_summary>This Phase I randomize double-blind , placebo-controlled , single multiple ascend dose study assess safety , tolerability pharmacokinetics AZD6765 healthy male female Japanese Caucasian subject</brief_summary>
	<brief_title>AZD6765 Single Multiple Ascending Dose Study Healthy Male Female Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>Body mass index ( BMI ) : 18 27 kg/m 2 Female subject must postmenopausal least 1 year , surgically sterile , use reliable method contraception screen . Male subject must willing use accept contraceptive method , avoid unprotected sex , donate sperm 3 month drug administration . Clinically relevant disease and/or abnormality ( past present ) Clinically relevant abnormality physical examination , vital sign , clinical chemistry , hematology urinalysis screen judge investigator Use prescription medication within 14 day Day 1 Use overthecounter ( OTC ) medication ( exception acetaminophen ) , vitamin/nutritional supplement herbal preparation within 14 day Day 1 Smoking excess 5 cigarette per day equivalent within 28 day Day 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>AZD6765</keyword>
	<keyword>Japanese Caucasian Healthy Volunteers</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Single multiple Ascending Dose</keyword>
	<keyword>Japanese volunteer</keyword>
</DOC>